{
    "predictions": [
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "bone- marrow",
            "begin": 7,
            "end": 18,
            "ner_label": "Site_Bone",
            "confidence": "0.74453336"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "BM",
            "begin": 21,
            "end": 22,
            "ner_label": "Site_Bone",
            "confidence": "0.7055"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "aspiration",
            "begin": 25,
            "end": 34,
            "ner_label": "Pathology_Test",
            "confidence": "0.776"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "positive",
            "begin": 84,
            "end": 91,
            "ner_label": "Biomarker_Result",
            "confidence": "0.978"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CD9",
            "begin": 97,
            "end": 99,
            "ner_label": "Biomarker",
            "confidence": "0.9962"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CD10",
            "begin": 102,
            "end": 105,
            "ner_label": "Biomarker",
            "confidence": "0.9989"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CD13",
            "begin": 108,
            "end": 111,
            "ner_label": "Biomarker",
            "confidence": "0.9981"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CD19",
            "begin": 114,
            "end": 117,
            "ner_label": "Biomarker",
            "confidence": "0.9984"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CD20",
            "begin": 120,
            "end": 123,
            "ner_label": "Biomarker",
            "confidence": "0.9983"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CD34",
            "begin": 126,
            "end": 129,
            "ner_label": "Biomarker",
            "confidence": "0.9952"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CD38",
            "begin": 132,
            "end": 135,
            "ner_label": "Biomarker",
            "confidence": "0.9974"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CD58",
            "begin": 138,
            "end": 141,
            "ner_label": "Biomarker",
            "confidence": "0.9995"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CD66c",
            "begin": 144,
            "end": 148,
            "ner_label": "Biomarker",
            "confidence": "0.9991"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CD123",
            "begin": 151,
            "end": 155,
            "ner_label": "Biomarker",
            "confidence": "0.9997"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "HLA-DR",
            "begin": 158,
            "end": 163,
            "ner_label": "Biomarker",
            "confidence": "0.9983"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "cCD79a",
            "begin": 166,
            "end": 171,
            "ner_label": "Biomarker",
            "confidence": "0.9308"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "TdT",
            "begin": 178,
            "end": 180,
            "ner_label": "Biomarker",
            "confidence": "0.9981"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "tumor markers",
            "begin": 224,
            "end": 236,
            "ner_label": "Biomarker",
            "confidence": "0.51035"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "elevated level",
            "begin": 245,
            "end": 258,
            "ner_label": "Biomarker_Result",
            "confidence": "0.87855"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "cytokeratin 19 fragment",
            "begin": 263,
            "end": 285,
            "ner_label": "Biomarker",
            "confidence": "0.9396667"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "Cyfra21-1",
            "begin": 288,
            "end": 296,
            "ner_label": "Biomarker",
            "confidence": "0.8252"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "4.77 ng/mL",
            "begin": 299,
            "end": 308,
            "ner_label": "Biomarker_Result",
            "confidence": "0.97945"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "neuron-specific enolase",
            "begin": 312,
            "end": 334,
            "ner_label": "Biomarker",
            "confidence": "0.90805"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "NSE",
            "begin": 337,
            "end": 339,
            "ner_label": "Biomarker",
            "confidence": "0.9965"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "19.60 ng/mL",
            "begin": 342,
            "end": 352,
            "ner_label": "Biomarker_Result",
            "confidence": "0.93895"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "squamous cell",
            "begin": 360,
            "end": 372,
            "ner_label": "Histological_Type",
            "confidence": "0.92120004"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "carcinoma",
            "begin": 374,
            "end": 382,
            "ner_label": "Cancer_Dx",
            "confidence": "0.7278"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "SCCA",
            "begin": 393,
            "end": 396,
            "ner_label": "Biomarker",
            "confidence": "0.9905"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "2.58 ng/mL",
            "begin": 399,
            "end": 408,
            "ner_label": "Biomarker_Result",
            "confidence": "0.96415"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "negative",
            "begin": 429,
            "end": 436,
            "ner_label": "Biomarker_Result",
            "confidence": "0.9964"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "serum carbohydrate antigen 125",
            "begin": 442,
            "end": 471,
            "ner_label": "Biomarker",
            "confidence": "0.82739997"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CA125",
            "begin": 474,
            "end": 478,
            "ner_label": "Biomarker",
            "confidence": "0.9991"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "carcinoembryonic antigen",
            "begin": 482,
            "end": 505,
            "ner_label": "Biomarker",
            "confidence": "0.99619997"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CEA",
            "begin": 508,
            "end": 510,
            "ner_label": "Biomarker",
            "confidence": "0.9993"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "vascular endothelial growth factor",
            "begin": 517,
            "end": 550,
            "ner_label": "Biomarker",
            "confidence": "0.84685004"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "VEGF",
            "begin": 553,
            "end": 556,
            "ner_label": "Biomarker",
            "confidence": "0.9606"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "Immunohistochemical staining",
            "begin": 560,
            "end": 587,
            "ner_label": "Pathology_Test",
            "confidence": "0.9282"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "positive",
            "begin": 596,
            "end": 603,
            "ner_label": "Biomarker_Result",
            "confidence": "0.9985"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "CK5/6",
            "begin": 618,
            "end": 622,
            "ner_label": "Biomarker",
            "confidence": "0.9996"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "P40",
            "begin": 625,
            "end": 627,
            "ner_label": "Biomarker",
            "confidence": "0.9954"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "PD-L1",
            "begin": 633,
            "end": 637,
            "ner_label": "Biomarker",
            "confidence": "0.988"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "+",
            "begin": 640,
            "end": 640,
            "ner_label": "Biomarker_Result",
            "confidence": "0.9292"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "80% tumor cells",
            "begin": 642,
            "end": 656,
            "ner_label": "Pathology_Result",
            "confidence": "0.7260333"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "negative",
            "begin": 664,
            "end": 671,
            "ner_label": "Biomarker_Result",
            "confidence": "0.999"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "TTF-1",
            "begin": 686,
            "end": 690,
            "ner_label": "Biomarker",
            "confidence": "0.9941"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "PD-1",
            "begin": 693,
            "end": 696,
            "ner_label": "Biomarker",
            "confidence": "0.9987"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "weakly positive",
            "begin": 702,
            "end": 716,
            "ner_label": "Biomarker_Result",
            "confidence": "0.97720003"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "ALK",
            "begin": 731,
            "end": 733,
            "ner_label": "Oncogene",
            "confidence": "0.9956"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "Molecular analysis",
            "begin": 736,
            "end": 753,
            "ner_label": "Pathology_Test",
            "confidence": "0.86785"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "EGFR",
            "begin": 768,
            "end": 771,
            "ner_label": "Oncogene",
            "confidence": "0.9932"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "mutation",
            "begin": 773,
            "end": 780,
            "ner_label": "Biomarker_Result",
            "confidence": "0.5719"
        },
        {
            "document": "In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9, CD10, CD13, CD19, CD20, CD34, CD38, CD58, CD66c, CD123, HLA-DR, cCD79a, and TdT on flow cytometry.\n\nMeasurements of serum tumor markers showed elevated level of cytokeratin 19 fragment (Cyfra21-1: 4.77 ng/mL), neuron-specific enolase (NSE: 19.60 ng/mL), and squamous cell carcinoma antigen (SCCA: 2.58 ng/mL). The results were negative for serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). Immunohistochemical staining showed positive staining for CK5/6, P40 and PD-L1 (+ 80% tumor cells), and negative staining for TTF-1, PD-1 and weakly positive staining for ALK. Molecular analysis indicated no EGFR mutation or ROS1 fusion.",
            "ner_chunk": "ROS1",
            "begin": 785,
            "end": 788,
            "ner_label": "Oncogene",
            "confidence": "0.9715"
        }
    ]
}